Novartis AG NVS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.52B | 14.41B | 13.11B | 13.34B | 13.91B |
| Total Other Revenue | 507.00M | 543.00M | 411.00M | 524.00M | 449.00M |
| Total Revenue | 15.03B | 14.95B | 13.52B | 13.86B | 14.36B |
| Cost of Revenue | 3.57B | 3.68B | 3.44B | 3.54B | 3.54B |
| Gross Profit | 11.46B | 11.27B | 10.09B | 10.32B | 10.82B |
| SG&A Expenses | 3.08B | 3.23B | 3.14B | 3.44B | 3.31B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 250.00M | 127.00M | 42.00M | 190.00M | 137.00M |
| Total Operating Expenses | 9.88B | 9.78B | 9.40B | 10.01B | 9.93B |
| Operating Income | 5.15B | 5.18B | 4.12B | 3.86B | 4.43B |
| Income Before Tax | 1.32B | 4.27B | 3.84B | 3.22B | 4.20B |
| Income Tax Expenses | 121.00M | 1.01B | 683.00M | 814.00M | 266.00M |
| Earnings from Continuing Operations | 1.20B | 3.26B | 3.16B | 2.40B | 3.93B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.00M | 7.00M | -- | 5.00M | -2.00M |
| Net Income | 1.20B | 3.26B | 3.16B | 2.41B | 3.93B |
| EBIT | 5.15B | 5.18B | 4.12B | 3.86B | 4.43B |
| EBITDA | 6.38B | 6.30B | 5.24B | 4.96B | 5.62B |
| EPS Basic | 0.63 | 1.71 | 1.65 | 1.26 | 2.04 |
| Normalized Basic EPS | 1.54 | 1.56 | 1.24 | 1.14 | 1.34 |
| EPS Diluted | 0.63 | 1.71 | 1.65 | 1.25 | 2.02 |
| Normalized Diluted EPS | 1.53 | 1.55 | 1.23 | 1.13 | 1.33 |
| Average Basic Shares Outstanding | 1.90B | 1.91B | 1.91B | 1.91B | 1.93B |
| Average Diluted Shares Outstanding | 1.91B | 1.91B | 1.92B | 1.93B | 1.94B |
| Dividend Per Share | -- | -- | -- | 4.67 | -- |
| Payout Ratio | -- | 87.96% | 196.36% | 0.00% | -- |